Prof Jayesh Desai
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
492 Scholarly works
25 Projects
HIGHLIGHTS
2026
Journal article
Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial
DOI: 10.1038/s41698-025-01253-52026
Journal article
Intratumoral heterogeneity and immunotherapy resistance: clinical implications.
DOI: 10.1016/j.annonc.2025.10.12392026
Journal article
Abstract PS1-10-07: Progression free survival and exploratory endpoints from PALVEN: a phase 1b study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
DOI: 10.1158/1557-3265.sabcs25-ps1-10-072022
Research contracts (non-grants)
Cancer State-Wide Project (iPREDICT2 Study)
2021
Research Contracts
VCCC Alliance Program Agreement
2020
Research contracts (non-grants)
MoST Molecular Screening
2019
Journal article
A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2– positive metastatic breast cancer
DOI: 10.1158/2159-8290.CD-18-1151
RECENT SCHOLARLY WORKS
2026
Journal article
The value of a second expert opinion in histopathological diagnosis of bone and soft tissue sarcoma: a systematic review
DOI: 10.1016/j.pathol.2025.09.0052026
Journal article
Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).
DOI: 10.1200/jco.2026.44.2_suppl.6542026
Journal article
BREAKWATER: Primary analysis of first-line (1L) encorafenib cetuximab (EC) FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
DOI: 10.1200/jco.2026.44.2_suppl.132026
Journal article
Genomic Therapy Matching in Rare and Refractory Cancers
DOI: 10.1001/jamaoncol.2026.01272026
Journal article
Clinical Utility of an RNA-based Gene Fusion Assay in Sarcoma for Diagnosis and Management: Experience in an Australian Laboratory
DOI: 10.1007/s40291-025-00820-72025
Journal article
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
DOI: 10.1038/s41591-025-04029-32025
Journal article
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions
DOI: 10.1200/PO-25-00221
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
A vaLue-based Person-Centric Enhanced Health Technology Assessment in CAncer Medicine (ALPACA)